DDInter596 DDInter1024
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Doxorubicin {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Lapatinib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lapatinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is bound by {v} (Compound) Lapatinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) HERC6
HERC6 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Lapatinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) IL4R
IL4R {u} (Gene) is downregulated by {v} (Compound) Lapatinib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Nail disorder
Nail disorder {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Doxorubicin {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is associated with {v} (Gene) ERBB4
ERBB4 {u} (Gene) is bound by {v} (Compound) Lapatinib
Doxorubicin (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Doxorubicin (Compound) downregulates ERBB2 (Gene) and ERBB2 (Gene) is bound by Lapatinib (Compound)
Doxorubicin (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is upregulated by Lapatinib (Compound)
Doxorubicin (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Lapatinib (Compound)
Doxorubicin (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Lapatinib (Compound)
Doxorubicin (Compound) upregulates IL4R (Gene) and IL4R (Gene) is downregulated by Lapatinib (Compound)
Doxorubicin (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Lapatinib (Compound)
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Doxorubicin (Compound) treats breast cancer (Disease) and breast cancer (Disease) is associated with ERBB4 (Gene) and ERBB4 (Gene) is bound by Lapatinib (Compound)